Literature DB >> 28115523

APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.

Xiaoyun Cheng1,2, Jun Yamauchi2, Sojin Lee2, Ting Zhang2, Zhenwei Gong2, Radhika Muzumdar2, Shen Qu3, H Henry Dong4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), characterized by excessive fat accumulation in liver, is prevalent in obesity. Genetic factors that link obesity to NAFLD remain obscure. Apolipoprotein C3 (APOC3) is a lipid-binding protein with a pivotal role in triglyceride metabolism. Humans with APOC3 gain-of-function mutations and mice with APOC3 overproduction are associated with hypertriglyceridemia. Nonetheless, it remains controversial whether APOC3 is culpable for diet-induced NAFLD. To address this fundamental issue, we fed APOC3-transgenic and wild-type littermates a high fructose diet or high fat diet, followed by determination of the effect of APOC3 on hepatic lipid metabolism and inflammation and the progression of NAFLD. To gain mechanistic insight into NAFLD, we determined the impact of APOC3 on hepatic triglyceride synthesis and secretion versus fatty acid oxidation. APOC3-transgenic mice were hypertriglyceridemic, culminating in marked elevation of triglycerides, cholesterols, and non-esterified fatty acids in plasma. Despite the prevailing hypertriglyceridemia, APOC3-transgenic mice, relative to wild-type littermates, had similar weight gain and hepatic lipid content without alterations in hepatic expression of key genes involved in triglyceride synthesis and secretion and fatty acid oxidation. APOC3-transgenic and wild-type mice had similar Kupffer cell content without alterations in hepatic expression of pro- and anti-inflammatory cytokines. APOC3 neither exacerbated diet-induced adiposity nor aggravated the degree of steatosis in high fructose or high fat-fed APOC3-transgenic mice. These effects ensued independently of weight gain even after 10-month high fat feeding. We concluded that APOC3, whose dysregulation is liable for hypertriglyceridemia, is not a predisposing factor for linking overnutrition to NAFLD in obesity.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Apolipoprotein C3; Hypertriglyceridemia; Nonalcoholic fatty liver disease; Steatosis; Triglyceride metabolism; apolipoprotein; lipid metabolism; liver; obesity; triglyceride

Mesh:

Substances:

Year:  2017        PMID: 28115523      PMCID: PMC5339753          DOI: 10.1074/jbc.M116.765917

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen.

Authors:  Wen Qin; Meenakshi Sundaram; Yuwei Wang; Hu Zhou; Shumei Zhong; Chia-Ching Chang; Sanjay Manhas; Erik F Yao; Robin J Parks; Pamela J McFie; Scot J Stone; Zhenghui G Jiang; Congrong Wang; Daniel Figeys; Weiping Jia; Zemin Yao
Journal:  J Biol Chem       Date:  2011-06-15       Impact factor: 5.157

2.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Authors:  Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

Review 3.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

4.  Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.

Authors:  M C Jong; P C Rensen; V E Dahlmans; H van der Boom; T J van Berkel; L M Havekes
Journal:  J Lipid Res       Date:  2001-10       Impact factor: 5.922

5.  ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression.

Authors:  Gery Gerritsen; Patrick C N Rensen; Kyriakos E Kypreos; Vassilis I Zannis; Louis M Havekes; Ko Willems van Dijk
Journal:  J Lipid Res       Date:  2005-05-01       Impact factor: 5.922

6.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

Review 7.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

8.  Proteomic analysis of fructose-induced fatty liver in hamsters.

Authors:  Lihe Zhang; German Perdomo; Dae Hyun Kim; Shen Qu; Steven Ringquist; Massimo Trucco; H Henry Dong
Journal:  Metabolism       Date:  2008-08       Impact factor: 8.694

9.  Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism.

Authors:  Yong Fan; Ram K Menon; Pinchas Cohen; David Hwang; Thomas Clemens; Douglas J DiGirolamo; John J Kopchick; Derek Le Roith; Massimo Trucco; Mark A Sperling
Journal:  J Biol Chem       Date:  2009-05-21       Impact factor: 5.157

10.  Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.

Authors:  M Chen; J L Breslow; W Li; T Leff
Journal:  J Lipid Res       Date:  1994-11       Impact factor: 5.922

View more
  6 in total

1.  Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr-/- Mice.

Authors:  Xueying Peng; Zeqin Lian; Xiao-Yuan Dai Perrard; Yunjie Xiao; Jing Ni; Veronica O'Brien; Henry Dong; Henry J Pownall; Christie M Ballantyne; Huaizhu Wu
Journal:  Cells       Date:  2022-05-30       Impact factor: 7.666

2.  APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Qing-Yang Xu; Han Li; Hai-Xia Cao; Qin Pan; Jian-Gao Fan
Journal:  Biomed Res Int       Date:  2020-11-26       Impact factor: 3.411

3.  Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.

Authors:  Songsong Wang; Feiya Sheng; Liang Zou; Jianbo Xiao; Peng Li
Journal:  J Adv Res       Date:  2021-06-08       Impact factor: 10.479

Review 4.  Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model".

Authors:  Yan-Lan Fang; Hong Chen; Chun-Lin Wang; Li Liang
Journal:  World J Gastroenterol       Date:  2018-07-21       Impact factor: 5.742

Review 5.  Metabolic-associated fatty liver disease and lipoprotein metabolism.

Authors:  Joerg Heeren; Ludger Scheja
Journal:  Mol Metab       Date:  2021-04-20       Impact factor: 7.422

Review 6.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.